Nevertheless, it is consistent with emerging evidence, including a recent meta-analysis reporting a 63% reduction in CA-AKI risk with SGLT2 inhibitors in diabetic patients undergoing coronary angiography or PCI [48] Similarly, a multicenter registry study conducted on patients with type 2 diabetes mellitus showed significantly lower CA-AKI incidence in SGLT2 inhibitor users after primary PCI [49]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.